AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Candesartan Effect in Second Stage Arterial Hypertension
Phase 4
Completed
- Conditions
- Stage II Hypertension
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2010-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 214
- Registration Number
- NCT00621153
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
CRESTOR Athero Imaging Head to Head IVUS Study
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2333
- Registration Number
- NCT00620542
- Locations
- 🇪🇸
Research Site, Alicante, Comunidad Valenciana, Spain
Atacand (Candesartan) Real Life Study
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14000
- Registration Number
- NCT00620178
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1494
- Registration Number
- NCT00617669
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Efficacy and Tolerability of Zolmitriptan Nasal Spray
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2009-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2114
- Registration Number
- NCT00617747
Cardiac Electrophysiological Study
Phase 2
Completed
- Conditions
- Atrial Flutter
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT00616629
- Locations
- 🇸🇪
Research Site, Ŏrebro, Sweden
Schizophrenic Patients Taking Part in Integrated Care Program
Terminated
- Conditions
- SchizophreniaSchizoaffective DisorderSchizophreni-form DisorderDelusional DisorderPsychotic Disorder Not Otherwise Specified
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00617214
- Locations
- 🇩🇪
Research Site, Zittau, Germany
AZD9773 Dose Escalation Study
Phase 2
Completed
- Conditions
- Severe Sepsis
- Interventions
- Drug: AZD9773 (CytoFab)Other: Placebo
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT00615017
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 572
- Registration Number
- NCT00614939
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients
Phase 1
Completed
- Conditions
- CancerTumorsCarcinoma
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2009-07-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00613652
- Locations
- 🇯🇵
Research Site, Fukuoka, Japan
© Copyright 2025. All Rights Reserved by MedPath